- Home
- MMTX vs RNXT Comparison
MMTX vs RNXT Comparison
Compare MMTX & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$1.68
Company Overview
Basic Information| Metric | MMTX | RNXT |
|---|---|---|
| Founded | 2025 | 2012 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.8M | 79.4M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MMTX | RNXT |
|---|---|---|
| Price | $10.19 | $1.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 18.1K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,123,000.00 |
| Revenue This Year | N/A | $194.66 |
| Revenue Next Year | N/A | $279.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $9.89 | $0.70 |
| 52 Week High | $10.21 | $2.59 |
Technical Indicators
Market Signals| Indicator | MMTX | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 57.12 | 48.00 |
| Support Level | $10.14 | $1.55 |
| Resistance Level | $10.21 | $2.59 |
| Average True Range (ATR) | 0.02 | 0.17 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 71.43 | 5.05 |
Price Performance
Historical Comparison MMTX
RNXT
About MMTX Miluna Acquisition Corp Class A Ordinary Share
Miluna Acquisition Corp is a blank check company.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.